Literature DB >> 11437503

A guinea-pig model of Hendra virus encephalitis.

M M Williamson1, P T Hooper, P W Selleck, H A Westbury, R F Slocombe.   

Abstract

Subcutaneous inoculation, but not intradermal (footpad) or intranasal inoculation, with high doses of Hendra virus (HeV) consistently produced disease in guinea-pigs. Of 15 subcutaneously inoculated animals, 14 developed vascular disease with positive HeV immunohistochemical labelling in a range of tissues. A new observation was the presence of lesions, including syncytial cells, with immunolabelling in the transitional epithelium of the bladder. Virus isolation from the urine rather than from nasal, oral, rectal or conjunctival swabs, the other external sites, was consistent with previous epidemiological work in horses, indicating a limited possibility of transmission. The dose used (30 000 to 50 000 TCID(50)), which was higher than in previous studies, produced microscopical lesions of encephalitis in eight of the 15 subcutaneously inoculated guinea-pigs, with positive immunolabelling in blood vessels and neurons, especially in the medulla, cerebellum and thalamus. The virus was recovered from six of the encephalitic brains. Severe vascular degeneration in the centres of encephalitic lesions in six of the eight encephalitic guinea-pigs and positive immunolabelling in the choroid plexus of a further animal indicated that the virus entered the brain following virus-induced vascular injury and choroid plexus invasion. Guinea-pigs would appear to be suitable for the study of HeV encephalitis.

Entities:  

Mesh:

Year:  2001        PMID: 11437503     DOI: 10.1053/jcpa.2001.0464

Source DB:  PubMed          Journal:  J Comp Pathol        ISSN: 0021-9975            Impact factor:   1.311


  19 in total

Review 1.  Hendra and nipah infection: pathology, models and potential therapies.

Authors:  Frederic Vigant; Benhur Lee
Journal:  Infect Disord Drug Targets       Date:  2011-06

2.  Hendra virus and Nipah virus animal vaccines.

Authors:  Christopher C Broder; Dawn L Weir; Peter A Reid
Journal:  Vaccine       Date:  2016-05-04       Impact factor: 3.641

3.  Invasion of the central nervous system in a porcine host by nipah virus.

Authors:  Hana Weingartl; Stefanie Czub; John Copps; Yohannes Berhane; Deborah Middleton; Peter Marszal; Jason Gren; Greg Smith; Shelley Ganske; Lisa Manning; Markus Czub
Journal:  J Virol       Date:  2005-06       Impact factor: 5.103

Review 4.  Henipavirus receptor usage and tropism.

Authors:  Olivier Pernet; Yao E Wang; Benhur Lee
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

5.  Development of an acute and highly pathogenic nonhuman primate model of Nipah virus infection.

Authors:  Thomas W Geisbert; Kathleen M Daddario-DiCaprio; Andrew C Hickey; Mark A Smith; Yee-Peng Chan; Lin-Fa Wang; Joseph J Mattapallil; Joan B Geisbert; Katharine N Bossart; Christopher C Broder
Journal:  PLoS One       Date:  2010-05-18       Impact factor: 3.240

6.  Nipah virus infection and glycoprotein targeting in endothelial cells.

Authors:  Stephanie Erbar; Andrea Maisner
Journal:  Virol J       Date:  2010-11-08       Impact factor: 4.099

7.  A golden hamster model for human acute Nipah virus infection.

Authors:  K Thong Wong; Isabelle Grosjean; Christine Brisson; Barissa Blanquier; Michelle Fevre-Montange; Arlette Bernard; Philippe Loth; Marie-Claude Georges-Courbot; Michelle Chevallier; Hideo Akaoka; Philippe Marianneau; Sai Kit Lam; T Fabian Wild; Vincent Deubel
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

8.  Targeted strategies for henipavirus therapeutics.

Authors:  Katharine N Bossart; John Bingham; Deborah Middleton
Journal:  Open Virol J       Date:  2007-09-28

9.  Experimental inoculation study indicates swine as a potential host for Hendra virus.

Authors:  Mingyi Li; Carissa Embury-Hyatt; Hana M Weingartl
Journal:  Vet Res       Date:  2010-01-20       Impact factor: 3.683

10.  Distinct and overlapping roles of Nipah virus P gene products in modulating the human endothelial cell antiviral response.

Authors:  Michael K Lo; Mark E Peeples; William J Bellini; Stuart T Nichol; Paul A Rota; Christina F Spiropoulou
Journal:  PLoS One       Date:  2012-10-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.